WARREN, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their...
NEW YORK , May 3, 2026 /PRNewswire/ --
NEW YORK , April 30, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST). Such...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their Options
Key Dates and Disclosure Events Shareholders Need to Know
Notice to Pension Funds, Asset Managers, and Fiduciaries
NEW YORK , April 28, 2026 /PRNewswire/ - The Gross Law Firm issues the following notice to shareholders of Aquestive Therapeutics, Inc. (NASDAQ: AQST) .
NEW YORK , April 27, 2026 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Aquestive...
NEW YORK , April 27, 2026 /PRNewswire/ --